--- title: "Seres Therap | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 736 K" type: "News" locale: "en" url: "https://longbridge.com/en/news/294955356.md" datetime: "2026-08-05T11:06:58.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294955356.md) - [en](https://longbridge.com/en/news/294955356.md) - [zh-HK](https://longbridge.com/zh-HK/news/294955356.md) generator: "portal-rs" --- # Seres Therap | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 736 K Revenue: As of FY2026 Q2, the actual value is USD 736 K, beating the estimate of USD 179 K. EPS: As of FY2026 Q2, the actual value is USD 0.47. EBIT: As of FY2026 Q2, the actual value is USD 4.4 M. ### Second Quarter 2026 Financial Results #### Net Income (Loss) - Seres Therapeutics, Inc. reported a net income of $4.6 million for the second quarter of 2026, compared to a net loss of - $19.9 million for the same period in 2025. This improvement was primarily due to a $25.0 million Gain on Sale of the VOWST Business recognized in the second quarter of 2026. #### Operating Expenses - **Research and development expenses** were $9.1 million for the second quarter of 2026, a decrease from $12.9 million in the second quarter of 2025, attributed to lower personnel-related expenses, facilities costs, transition services agreement (TSA) costs, and SER-155 costs. - **General and administrative expenses** decreased to $7.1 million for the second quarter of 2026, down from $10.3 million in the comparable 2025 period, due to lower personnel-related expenses, facilities costs, professional services fees, and IT costs. - **Manufacturing services expenses** were $0 million in the second quarter of 2026, compared to $1.7 million in the second quarter of 2025, as Seres Therapeutics, Inc. completed such services under the TSA at the end of 2025. - An **impairment charge** of $5.8 million was recorded in the second quarter of 2026 due to the early termination of a portion of the company’s leased space at 101 Cambridgepark Drive. #### Other Income - A **Gain on Sale of VOWST Business** of $25.0 million was recognized for the second quarter of 2026, compared to $0.185 million for the same period in 2025, resulting from a Milestone Termination Payment from Nestlé Health Science. #### Cash and Cash Runway - As of June 30, 2026, Seres Therapeutics, Inc. held cash and cash equivalents totaling $15.6 million. ### Operational Metrics and Corporate Updates - **SER-155 in irEC:** Positive topline results from an investigator-sponsored trial (IST) showed that 80% of 15 participants with moderate-to-severe irEC achieved an immunosuppressive-free clinical response at day 15. Seres Therapeutics, Inc. is evaluating its clinical development strategy and engaging potential partners for this program. - **SER-155 for allo-HCT:** The program remains Phase 2 ready for the prevention of bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HCT), holding Breakthrough Therapy and Fast Track designations, with the company seeking funding to advance it. - **Broader Pipeline:** Seres Therapeutics, Inc. is advancing IND-enabling activities for SER-603 for inflammatory bowel disease and progressing development of SER-428, an oral liquid formulation of SER-155 strains, for which a Phase 1b trial is being designed. - **Facilities Cost Reduction:** Seres Therapeutics, Inc. entered an agreement to terminate the lease for its facility at 200 Sidney Street, Cambridge, MA, which will eliminate remaining obligations as of December 31, 2026, and significantly reduce ongoing facility-related cash costs starting in 2027. This follows a June 2026 lease restructuring for its 101 CambridgePark Drive facility, which reduced leased space and related expenses. - **Nestlé Milestone Payment:** An amendment to the asset purchase agreement with Nestlé Health Science resulted in a $25 million Milestone Termination Payment, with $12.5 million received on July 1, 2026, and another $12.5 million expected on October 1, 2026. ### Outlook / Guidance Seres Therapeutics, Inc. expects to fund its operations through the first quarter of 2027 using its currently available cash resources, which include the remaining $12.5 million Milestone Termination Payment from Nestlé due October 1, 2026. This projection does not account for any proceeds from potential future partnerships or other sources of capital. The company is actively engaging potential partners and seeking capital to advance its SER-155 programs and broader inflammatory and immune portfolio. ### Related Stocks - [MCRB.US](https://longbridge.com/en/quote/MCRB.US.md) ## Related News & Research - [Seres Therapeutics, Inc. 2Q 2026: Revenue $0.736M, Net income $4.581M, EPS $0.47— 10-Q Summary](https://longbridge.com/en/news/294984192.md) - [WhiteFiber amends 8-K to file real estate purchase and sale agreement as exhibit](https://longbridge.com/en/news/297088090.md) - [DLTR: Q2 sales rose 7% with EPS of $2.70, strong margins, and raised fiscal 2026 outlook](https://longbridge.com/en/news/297169206.md) - [Northann amends 8-K to file former auditor LAO Professionals’ letter on resignation](https://longbridge.com/en/news/296825824.md) - [Synopsys lifts estimated pre-tax restructuring charges to $425 million-$500 million in 8-K amendment](https://longbridge.com/en/news/297088345.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**